CA2330049A1 - Hydroxyomeprazole compositions and uses - Google Patents

Hydroxyomeprazole compositions and uses Download PDF

Info

Publication number
CA2330049A1
CA2330049A1 CA002330049A CA2330049A CA2330049A1 CA 2330049 A1 CA2330049 A1 CA 2330049A1 CA 002330049 A CA002330049 A CA 002330049A CA 2330049 A CA2330049 A CA 2330049A CA 2330049 A1 CA2330049 A1 CA 2330049A1
Authority
CA
Canada
Prior art keywords
hydroxyomeprazole
pharmaceutically acceptable
acceptable salt
effective amount
therapeutically effective
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002330049A
Other languages
English (en)
French (fr)
Inventor
William E. Yelle
Dean A. Handley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sumitomo Pharma America Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2330049A1 publication Critical patent/CA2330049A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CA002330049A 1998-05-05 1999-05-05 Hydroxyomeprazole compositions and uses Abandoned CA2330049A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8425898P 1998-05-05 1998-05-05
US60/084,258 1998-05-05
PCT/US1999/009814 WO1999056746A1 (en) 1998-05-05 1999-05-05 Hydroxyomeprazole compositions and uses

Publications (1)

Publication Number Publication Date
CA2330049A1 true CA2330049A1 (en) 1999-11-11

Family

ID=22183810

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002330049A Abandoned CA2330049A1 (en) 1998-05-05 1999-05-05 Hydroxyomeprazole compositions and uses

Country Status (9)

Country Link
US (2) US6294586B1 (https=)
EP (1) EP1082114B1 (https=)
JP (1) JP2003517434A (https=)
AT (1) ATE222764T1 (https=)
AU (1) AU748872B2 (https=)
CA (1) CA2330049A1 (https=)
DE (1) DE69902657T2 (https=)
ES (1) ES2182524T3 (https=)
WO (1) WO1999056746A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6420435B1 (en) * 1999-11-01 2002-07-16 Joe S. Wilkins, Jr. Method for treating gastrointestinal disorders
US6987123B2 (en) 2001-07-26 2006-01-17 Cadila Healthcare Limited Heterocyclic compounds, their preparation, pharmaceutical compositions containing them and their use in medicine
US7041706B2 (en) * 2002-04-19 2006-05-09 Wilkins Jr Joe S Method for treating crohn's disease
WO2004064719A2 (en) * 2003-01-24 2004-08-05 State Of Israel, Ministry Of Agriculture Synergistic compositions and methods for potentiating anti-oxidative activity
WO2005032554A1 (en) 2003-10-03 2005-04-14 Astron Research Pvt. Ltd A novel transmucosal delivery system
ES2281292B1 (es) * 2006-03-08 2008-06-16 Quimica Sintetica S.A. Nuevas sales de esomeprazol. procedimiento de preparacion y composiciones farmaceuticas que las comprenden.

Also Published As

Publication number Publication date
WO1999056746A1 (en) 1999-11-11
EP1082114A1 (en) 2001-03-14
AU748872B2 (en) 2002-06-13
EP1082114B1 (en) 2002-08-28
US6294586B1 (en) 2001-09-25
ES2182524T3 (es) 2003-03-01
AU3971699A (en) 1999-11-23
ATE222764T1 (de) 2002-09-15
US6498171B2 (en) 2002-12-24
JP2003517434A (ja) 2003-05-27
DE69902657D1 (de) 2002-10-02
US20020010196A1 (en) 2002-01-24
DE69902657T2 (de) 2003-04-30

Similar Documents

Publication Publication Date Title
US20010025107A1 (en) S-lansoprazole compositions and methods
US20040171647A1 (en) S(-)rabeprazole compositions and methods
US6174902B1 (en) R-rabeprazole compositions and methods
AU748872B2 (en) Hydroxyomeprazole compositions and uses
EP1098648B1 (en) Pharmaceutical compositions comprising hydroxylansoprazole and uses thereof
AU747167B2 (en) Desmethylpantoprazole compositions and methods
AU3870599A (en) R-rabeprazole compositions and methods
US20060142346A1 (en) S-lansoprazole compositions and methods
AU2003268822A1 (en) R-raberprazole compositions and methods
AU2003257509A1 (en) S-rabeprazole compositions and methods
AU2003264624A1 (en) S-lansoprazole compositions and methods

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued